ERBB2 and breast carcinoma: A considerable proportion of patients had TNBC (28.6%), followed by luminal A (22.1%), HER2-enriched (18.8%), luminal B HER-2/neu- (17.5%) and luminal B HER-2/neu+ (13%) breast cancer.